What we do Blue Jet Healthcare Limited is a global pharmaceutical company specializing in advanced pharmaceutical intermediates, active pharmaceutical ingredients, contrast media intermediates, and high-intensity sweeteners. |
Founded in 1,968 |
Market share A leading supplier in the contrast media intermediates market with ~75% exports in key products from India, long-term contracts with top global players. |
Problem solved Provides high-quality, regulated pharmaceutical intermediates and APIs to ensure reliable supply to innovator companies, aiding in chronic disease management and diagnostics. |
Top clients or who we serve Serves multinational pharmaceutical companies, generic drug manufacturers, FMCG and agrochemical sectors; operates B2B CDMO business model. |
Key management Akshay Bansarilal Arora (Executive Chairman), Shiven Akshay Arora (Managing Director), V.K. Singh (COO), Ganesh Karuppannan (CFO). |
Our journey and innovations Founded in 1968, expanded from sweeteners to contrast media intermediates in 2000, APIs in 2002; acquired new manufacturing units and merged entities; advanced semi-automated plants commissioned. |
Where we operate India-based with a global export footprint serving regulated markets in Europe, North America, and Asia. |
Top products or what we offer Contrast media intermediates, high-intensity sweeteners like saccharin, pharmaceutical intermediates, and APIs focused on chronic therapeutic areas. |
Top brands Products largely industry segments rather than brands; known for high quality in contrast media intermediates and sweeteners, key revenue contributors. |
Raw materials needed Specialized chemical raw materials for pharmaceutical synthesis including iodinated compounds, organic intermediates, and sweetener precursors. |
Raw materials supplier Proprietary supply chains, details not publicly disclosed, focusing on reliability and regulatory compliance. |
Recurring vs cyclical contribution Revenue largely recurring with long-term supply contracts but subject to some cyclicality based on pharma demand and regulatory approvals. |
Our industry position Among top suppliers globally in contrast media intermediates; significant market share and recognized for quality and regulatory compliance. |
Financial highlights FY25 revenue Rs 10,300 million; PAT Rs 3,052 million; EBITDA margin ~36.7%; strong growth driven by pharmaceutical intermediates and contrast media. |
Geographical revenue split Dominant exports (~85%) with significant domestic sales; exports to regulated markets like USA, Europe, and Asia. |
Order book Details not specified; long-term contracts provide revenue visibility especially in contrast media intermediates. |
Whats driving growth Increased demand for diagnostic agents, chronic disease pharmaceuticals, import substitution, and investments in R&D and manufacturing capacity. |
Our future plans Expand production capacity, R&D investment, develop advanced intermediates, and enter new pharma intermediate adjacencies. |
Our green promise Investments in renewable energy, effluent treatment, solvent recycling, and carbon footprint reduction efforts. |
Our people and values Experienced management, focus on compliance, safety, and employee welfare; commitment to ethics and governance. |
Key challenges ahead Market competition, regulatory hurdles, supply chain risks, and product mix volatility. |
Interesting facts Commissioned a significant 120 KL capacity plant for pharma intermediates recently; long-standing customer ties of up to 26 years. |
Risks and strategy Mitigates risks through strong customer relationships, diversified portfolio, continuous R&D, and adherence to regulatory standards. |
